Overview

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
Phase:
Phase 3
Details
Lead Sponsor:
American Genomics, LLC
Treatments:
Carticaine